Activist shareholders in 2014 helped the mergers and acquisitions landscape return to the pre-crisis days of 2007 – and they'll continue to make news.» Read More
Allergan rose $1.57 or. 7 percent, to $221.59. Baxter International Inc. rose$. 06 or. 1 percent, to $71.87. Boston Scientific Corp. rose$. 05 or. 3 percent, to $14.38.
Allergan rose $1.36 or. 6 percent, to $220.02. Baxter International Inc. fell$. 20 or. 3 percent, to $71.81. Boston Scientific Corp. fell$. 13 or. 9 percent, to $14.33.
Allergan rose$. 24 or. 1 percent, to $218.90. Baxter International Inc. fell$. 16 or. 2 percent, to $71.85. Boston Scientific Corp. fell$. 14 or 1.0 percent, to $14.32.
NEW YORK— Hedge fund Pershing Square Capital Management on Tuesday named Stephen Fraidin as its vice chairman, touting his experience in mergers and acquisitions. Pershing Square, which is run by activist investor Bill Ackman, said Fraidin was an adviser on its unsuccessful bid for Botox maker Allergan and has been a key adviser on other important investments.
Allergan fell$. 46 or. 2 percent, to $218.21. Baxter International Inc. fell$. 36 or. 5 percent, to $71.65. Boston Scientific Corp. fell$. 04 or. 3 percent, to $14.42.
Allergan rose $2.96 or 1.4 percent, to $218.66. Baxter International Inc. rose$. 53 or. 7 percent, to $72.01. Boston Scientific Corp. rose$. 15 or 1.0 percent, to $14.46.
BOSTON, Jan 16- Eric Mindich's $8.5 billion hedge fund, Eton Park Capital Management, is now ready to pick through the debt of beaten-up energy companies, an area it avoided last year as the price of oil tumbled. Eton Park dropped mortgage companies Fannie Mae and Freddie Mac with a big profit before a U.S. judge threw out a lawsuit filed by shareholders to prevent the...
Allergan rose $2.07 or 1.0 percent, to $217.77. Baxter International Inc. rose$. 32 or. 4 percent, to $71.80. Boston Scientific Corp. rose$. 07 or. 5 percent, to $14.38.
Allergan rose$. 96 or. 4 percent, to $216.66. Boston Scientific Corp. fell$. 06 or. 4 percent, to $14.25. Johnson& Johnson fell$. 06 or. 1 percent, to $102.43.
SAN FRANCISCO, Jan 15- Allergan Inc Chief Executive David Pyott is close to joining the board of directors of Actavis Plc, which reached a deal to buy the Botox-maker for $66 billion in November, three people familiar with the matter said on Thursday. One investor who attended the meeting told Reuters that adding Pyott to the board could lend more credibility to...
Martin D. Sass' stock picks are trades in three popular sectors: airlines, pharmaceuticals and asset management.
Roughly two years after promising to donate his personal winnings from his controversial $1 billion bet against nutritional and weight-loss company Herbalife Ltd., the hedge fund titan is making good on the pledge with a $10 million donation to a scholarship charity, his foundation said. Herbalife stock closed 2015' s first week of trading down 12 percent at...
"Mad Money" host Jim Cramer on the players that could keep tearing it up in 2015.
Jim Cramer reviews the Top 10 stocks of the S&P 500 for 2014. Will they be winners again this year?
Bill Ackman renewed his attack on Herbalife during a CNBC interview Wednesday, likening the nutrition and weight management company to Bernie Madoff.
On a down day in the market, Jim Cramer thinks this is the perfect time to review the silly preconceptions of 2014.
Critics love to hate hedge fund fees and performance, but the industry is poised to grow even more in 2015.
CNBC's Kate Kelly reveals what investors can expect from hedge funds and activists in 2015.
Mergers and acquisitions broke a seven-year losing streak in 2014, with $3.48 trillion worth of deals. CNBC looks at some of the year's highlights.
Dec 19- Shares in Spanish drugmaker Almirall jumped 9 percent on Friday after a Bloomberg report of potential takeover interest from Actavis. Almirall played down the report, saying in a regulatory filing that "the news is untrue." Almirall, with a market value of 2.3 billion euros, recently sold its respiratory business to AstraZeneca, while Actavis is in the...